Last reviewed 2026-04-23 · How we verify

Paclitaxel+Carboplatin/concurrent radiation

Paclitaxel+Carboplatin/concurrent radiation is a Chemotherapy combination with radiation Small molecule drug developed by West Japan Thoracic Oncology Group. It is currently in Phase 3 development for Locally advanced non-small cell lung cancer (NSCLC), Unresectable stage III NSCLC.

Paclitaxel and carboplatin chemotherapy combined with concurrent radiation therapy work synergistically to damage cancer cell DNA and inhibit microtubule function, while radiation enhances cytotoxic effects.

Paclitaxel and carboplatin chemotherapy combined with concurrent radiation therapy work synergistically to damage cancer cell DNA and inhibit microtubule function, while radiation enhances cytotoxic effects. Used for Locally advanced non-small cell lung cancer (NSCLC), Unresectable stage III NSCLC.

At a glance

Mechanism of action

Paclitaxel stabilizes microtubules and prevents cell division, while carboplatin is a platinum-based alkylating agent that cross-links DNA. When combined with concurrent radiation therapy, the chemotherapy agents enhance radiosensitivity of tumor cells, leading to increased DNA damage and apoptosis. This multimodal approach is particularly effective for locally advanced cancers where combined systemic and local control is needed.

Approved indications

• Locally advanced non-small cell lung cancer (NSCLC)
• Unresectable stage III NSCLC

Common side effects

• Neutropenia
• Anemia
• Thrombocytopenia
• Nausea/vomiting
• Esophagitis
• Pneumonitis
• Peripheral neuropathy
• Fatigue

Key clinical trials

• Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer (PHASE3)
• A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC (PHASE2)
• Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer (PHASE1)
• Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery (PHASE2)
• A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC) (PHASE2)
• A Study of Reduced Radiation Therapy With Chemotherapy in People With HPV-Positive Throat Cancer (PHASE2)
• A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer (PHASE2)
• Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Paclitaxel+Carboplatin/concurrent radiation CI brief — competitive landscape report
• Paclitaxel+Carboplatin/concurrent radiation updates RSS · CI watch RSS
• West Japan Thoracic Oncology Group portfolio CI

Frequently asked questions about Paclitaxel+Carboplatin/concurrent radiation

Related

• Drug class: All Chemotherapy combination with radiation drugs
• Manufacturer: West Japan Thoracic Oncology Group — full pipeline
• Therapeutic area: All drugs in Oncology
• Indication: Drugs for Locally advanced non-small cell lung cancer (NSCLC)
• Indication: Drugs for Unresectable stage III NSCLC